iMDK
CAS No. 881970-80-5
iMDK( —— )
Catalog No. M28701 CAS No. 881970-80-5
iMDK quarterhydrate is a potent PI3K inhibitor that inhibits the growth factor MDK (also known as midkine or MK). iMDK quarterhydrate synergistically inhibits non-small cell lung cancer (NSCLC) with MEK inhibitors without harming normal cells and mice.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 132 | In Stock |
|
| 5MG | 122 | In Stock |
|
| 10MG | 187 | In Stock |
|
| 25MG | 390 | In Stock |
|
| 50MG | 538 | In Stock |
|
| 100MG | 747 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameiMDK
-
NoteResearch use only, not for human use.
-
Brief DescriptioniMDK quarterhydrate is a potent PI3K inhibitor that inhibits the growth factor MDK (also known as midkine or MK). iMDK quarterhydrate synergistically inhibits non-small cell lung cancer (NSCLC) with MEK inhibitors without harming normal cells and mice.
-
DescriptioniMDK quarterhydrate is a potent PI3K inhibitor that inhibits the growth factor MDK (also known as midkine or MK). iMDK quarterhydrate synergistically inhibits non-small cell lung cancer (NSCLC) with MEK inhibitors without harming normal cells and mice.(In Vitro):Administration of iMDK (50-500 nM) for 72 h quarterhydrate suppressed AKT phosphorylation in H441 lung adenocarcinoma cells after treatment dose-dependently. In contrast, iMDK quarterhydrate robustly increases p-ERK.(In Vivo):Intraperitoneally injection with 100 μl of iMDK ( (9 mg/kg/day) and ; oral administion of PD0325901 (5 mg/kg) effectively reduced lung tumor growth in a xenograft mouse model.
-
In VitroCell Viability Assay Cell Line:H441 (lung adenocarcinoma; KRASG12V), H2009 (non-small cell carcinoma; KRASG12A), A549 (lung carcinoma; KRASG12S) and H520 (lung squamous cell carcinoma; KRASWT) Concentration:iMDK (2.5 μM) and PD0325901 (0.5 μM) for H441 and H2009 cells iMDK (0.125 μM) and PD0325901 (0.25 μM) for H520 cells iMDK (0.25 μM) and PD0325901 (0.125 μM) for A549 cells Incubation Time:72 hours Result:iMDK alone did not inhibit cell viability of A549 cells, the combinatorial treatment of iMDK with PD0325901 significantly inhibited that of A549 cells compared to the single treatment of PD0325901.Western Blot Analysis Cell Line:H441 lung adenocarcinoma cells Concentration:0-500 nM Incubation Time:72 hours Result:Suppressed AKT phosphorylation in a dose-dependent manner.ERK1/2 phosphorylation was increased.
-
In VivoAnimal Model:female BALB/c nude mice (6 week old) bearing H441 human lung cancer xenografts Dosage:iMDK (9 mg/kg) and PD0325901 (5 mg/kg) Administration:Intraperitoneally injected with 100 μL iMDK everyday and/or orally administered PD0325901 five times per week (on days 1, 2, 3, 4, 5, 7, 8, 9, 10, 11)Result:Reduced significantly volume of the tumors derived from H441 lung adenocarcinoma cells after the combination treatment with iMDK and PD0325901 compared to that of single compound in a xenograft mouse model.
-
Synonyms——
-
PathwayPI3K/Akt/mTOR signaling
-
TargetPI3K
-
RecptorTRPV1
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number881970-80-5
-
Formula Weight376.41
-
Molecular FormulaC21H13FN2O2S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 3.33 mg/mL (8.85 mM)
-
SMILESFc1ccc(Cc2cn3cc(nc3s2)-c2cc3ccccc3oc2=O)cc1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Gomtsyan A, et al. Identification of (R)-1-(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-4-yl)urea (ABT-102) as a potent TRPV1 antagonist for pain management. J Med Chem. 2008 Feb 14;51(3):392-5.
molnova catalog
related products
-
Idelalisib
Idelalisib (CAL-101, GS-1101) is a potent, selective inhibitor of PI3K p110δ with IC50 of 2.5 nM.
-
GDC-0326
A potent, selective, orally available PI3Kα inhibitor with Ki of 0.2 nM; displays 133, 20 and 33-fold selectivity over PI3Kβ, PI3Kδ and PI3Kγ, respectively.
-
LY3023414
LY3023414 is a potent, dual PI3K/mTOR inhibitor.
Cart
sales@molnova.com